U.S. Medical Equipment Stock News

Tokenized cash platform puts CME Group (CME) in focus CME Group (CME) is drawing fresh attention after partnering with Bank of Montreal and Google Cloud on a tokenized cash and deposit platform that enables 24/7 institutional settlement and collateral movements. See our latest analysis for CME Group. The recent tokenized cash announcement comes after a period of mixed momentum for CME Group, with a recent 1-day share price return of a 2.89% decline and a 7-day share price return of a 4.85%...

Omnicom Group overview Omnicom Group (OMC) has drawn investor attention after recent trading left the shares around $75.74, with returns negative over the past month, past 3 months, year to date, and past year. See our latest analysis for Omnicom Group. Recent trading reflects fading momentum, with a 30 day share price return showing a 6.20% decline and a 1 year total shareholder return showing a 2.98% decline, despite a positive 5 year total shareholder return of 21.77%. If you are weighing...

Wondering if Albemarle at a last close of US$181.39 still offers value, or if the best gains are already in the rearview mirror. The stock has returned 9.4% over the last 7 days, 2.2% over 30 days, 26.0% year to date, and 143.8% over the past year, while the 3 year and 5 year returns sit at negative 15.5% and 31.7% respectively. Those swings in performance set the scene for a closer look at what might be driving sentiment, from changing expectations around Albemarle's end markets to shifting...

In early 2026, Definium Therapeutics, formerly Mind Medicine, gained fresh attention after completing enrollment for its Phase III Emerge trial of DT120 in major depressive disorder and advancing toward multiple pivotal readouts in generalized anxiety and depression later in the year. This pipeline progress, alongside an early-stage program in autism spectrum disorder, is prompting investors to reassess how close Definium may be to shifting from pure R&D toward potential commercialization in...

Braze (BRZE) just closed out FY 2026 with fourth quarter revenue of US$205.2 million and a basic EPS loss of US$0.29, while the trailing twelve months show revenue of US$738.2 million and a full year basic EPS loss of US$1.22. Over recent periods, the company has seen quarterly revenue move from US$160.4 million in Q4 FY 2025 to US$205.2 million in Q4 FY 2026, with basic EPS losses in those quarters of US$0.17 and US$0.29 respectively. With losses still weighing on margins, the latest numbers...

Velo3D (VELO) has released its latest FY 2025 figures, reporting Q3 revenue of US$13.6 million and a basic EPS loss of US$0.69, alongside net income excluding extra items of a US$11.8 million loss. This keeps the focus firmly on profitability rather than the top line alone. Over recent quarters, the company’s revenue moved from US$8.2 million in Q3 2024 to US$13.6 million in Q3 2025, while basic EPS shifted from a loss of US$37.54 to a loss of US$0.69 as net losses moved from US$23.1 million...

What Huntsman’s Hungary expansion means for the stock Huntsman (HUN) has drawn fresh attention after opening an expanded Performance Products facility in Petfurdo, Hungary. The project increases global capacity with support from a local government investment grant and targets polyurethane, coatings, metalworking and electronics customers. See our latest analysis for Huntsman. The Hungary expansion comes as Huntsman’s share price has climbed 21.39% year to date and 24.95% over 90 days, while...

This article examines whether Natera, at around US$197 a share, still aligns with its underlying worth or whether expectations have already been priced in. The stock has delivered a 31.7% return over the last year and a large 3-year return of about 3.5x, even though the year-to-date move is a 13.8% decline and the last 30 days show a 5.7% decline. Recent coverage around Natera has focused on its position in the pharmaceuticals and biotech space, with investors closely watching how its...

Earlier this week, Royal Gold was caught in a sector-wide reaction as gold futures fell sharply following former President Donald Trump’s ultimatum that the U.S. would strike Iranian power plants if the Strait of Hormuz was not reopened within 48 hours. This episode highlights how sudden geopolitical tensions can quickly shift expectations for companies linked to gold prices, even without any change in their underlying operations. With gold futures under pressure amid these geopolitical...

Winnebago Industries (WGO) has put fresh numbers on the table, with Q1 2026 revenue of US$702.7 million and basic EPS of US$0.20 setting the tone for its latest update. Over recent quarters, revenue has moved between US$620.2 million and US$777.3 million, while basic EPS has ranged from a loss of US$1.01 to a profit of US$0.63. Trailing twelve month EPS sits at US$1.30 on revenue of about US$2.9 billion, which feeds into forecasts for earnings growth and a closer look at how margins are...

Earlier in March 2026, Pindrop announced an expanded integration with Zoom Contact Center, embedding real-time AI-driven deepfake detection, voice authentication and fraud risk intelligence into Zoom’s customer experience platform across multiple regulated industries. This move highlights how Zoom is extending its AI capabilities beyond productivity into identity trust and security, positioning its platform more deeply within critical enterprise workflows where fraud prevention is...

Wondering whether Turning Point Brands at around US$88 per share still offers value, or if most of the upside is already reflected in the price? This article walks through what the current market tag might be saying. The stock has been volatile recently, with a 34.9% decline over the last 30 days, even though the 1 year return stands at 50.0% and the 3 year return is a very large gain. Recent coverage has focused on how investors are reassessing consumer and tobacco related names, with...

StubHub Holdings (STUB) has drawn attention after recent trading, with the share price closing at US$6.87 and showing a return of about 4.2% over the latest session. See our latest analysis for StubHub Holdings. The latest 1 day share price return of 4.3% comes after a weaker patch. The 30 day share price return of 26.2% and year to date share price return of 51.9% both point to fading momentum rather than a quick reversal. If this kind of volatility has you looking at alternatives, it could...

KNOT Offshore Partners (NYSE:KNOP) has reported third quarter FY 2025 revenue of US$96.9 million and basic EPS of US$0.43, alongside net income of US$15.1 million, putting concrete numbers around its recent return to profitability. Over the last few reported periods, revenue has moved from US$74.3 million and EPS of US$0.32 loss in Q2 2024 to US$86.5 million with EPS of US$0.24 in Q2 2025, before reaching the latest US$96.9 million and US$0.43. This progression gives investors a clearer read...

Baozun (NasdaqGS:BZUN) has just posted its FY 2025 third quarter scorecard, with revenue of C¥2,156.2 million and a basic EPS loss of C¥1.85 per share, while trailing twelve month revenue sits at about C¥9.8 billion against a net loss of C¥204.0 million. Over recent quarters, the company has seen revenue range from C¥2,390.9 million in Q2 2024 to C¥2,552.7 million in Q2 2025, with basic EPS shifting between a small profit of C¥0.00 per share in Q4 2024 and losses such as C¥1.48 per share in...

Why Campbell's stock is on investors’ radar Campbell's (CPB) has drawn fresh attention after a roughly 23% decline over the past month, prompting investors to reassess how its current valuation lines up with its earnings profile and branded food portfolio. See our latest analysis for Campbell's. That recent 23% 30 day share price decline, alongside a 1 year total shareholder return of 44% in the red and a 57% total return drop over 3 years, suggests momentum has been fading even as investors...

Noah Holdings (NYSE:NOAH) has wrapped up FY 2025 with fourth quarter revenue of C¥733.2 million and net income, excluding extra items, of C¥12.8 million, setting the stage for investors to reassess the story at a share price of US$11.33. Over the past few quarters, the company has seen quarterly revenue move from C¥651.9 million in Q4 2024 to C¥614.6 million, C¥629.5 million and C¥632.9 million in the first three quarters of 2025. Over the same period, basic EPS stepped from C¥1.56 in Q4 2024...

If you are wondering whether Hilton Worldwide Holdings at around US$303 per share offers fair value or is pricing in too much optimism, this breakdown will help you frame the stock through several valuation lenses. The share price closed at US$303.16, with returns of 2.9% over 7 days, a 2.8% decline over 30 days, 3.5% year to date, 29.4% over 1 year, 125.0% over 3 years and 154.0% over 5 years. This raises clear questions about what is already reflected in the price. Recent coverage has...

EDAP TMS (NasdaqGM:EDAP) has reported Q3 2025 revenue of €13.9 million, with a basic EPS loss of €0.13 and net income loss of €5.0 million, while the trailing twelve months show revenue of €63.8 million, basic EPS loss of €0.52 and a net income loss of €19.6 million. Over recent quarters, the company has reported revenue of €13.1 million in Q3 2024, €20.3 million in Q4 2024 and €16.0 million in Q2 2025. Quarterly EPS losses have ranged from €0.05 in Q4 2024 to €0.19 in Q1 2025. This...

Waterdrop (NYSE:WDH) has put solid numbers on the table for FY 2025 so far, with third quarter revenue of ¥974.9 million and basic EPS of ¥0.44, alongside trailing 12 month EPS of ¥1.40 supported by net income of ¥506.4 million on revenue of ¥3.25 billion. Over recent quarters the company has seen revenue move from ¥676.2 million in Q2 2024 to ¥753.7 million in Q1 2025 and then to ¥974.9 million in Q3 2025. Basic EPS progressed from ¥0.24 in Q2 2024 to ¥0.30 in Q1 2025 and ¥0.44 in Q3 2025,...

The U.S. FDA has issued a warning letter to ImmunityBio over allegedly false and misleading promotional claims for its bladder cancer drug Anktiva. The letter focuses on how Anktiva has been marketed to healthcare professionals and patients, and requests corrective action from the company. This regulatory action introduces additional marketing and compliance risk for ImmunityBio at a time when its drug portfolio is gaining wider attention. For investors following ImmunityBio, ticker...

Occidental Petroleum has completed the sale of its OxyChem chemical business for about US$9.70 billion, directing the proceeds toward debt reduction and sharpening its focus on core oil and gas operations. This portfolio shift, alongside planned 2026 capital investment of US$5.50 billion to US$5.90 billion, marks a meaningful rebalancing of the company toward its highest-priority energy assets. Next, we’ll examine how this OxyChem divestment and debt reduction effort could reshape Occidental...

Formula One Group (FWON.K) is facing fresh scrutiny after canceling its Bahrain and Saudi Arabia grands prix because of escalating conflict in the Middle East, removing two high-fee races from its current calendar. See our latest analysis for Formula One Group. The recent cancellations come at a time when Formula One Group’s share price has a 90 day share price return of a 14% decline and a year to date share price return of a 15% decline. Meanwhile, the 5 year total shareholder return of 99%...

If you are wondering whether Danaher at around US$187 per share is starting to look appealing, or if the market still has it priced richly, this breakdown will help you frame that question clearly. The stock has recently been under pressure, with returns of a 2.3% decline over 7 days, 11.3% decline over 30 days, 18.8% decline year to date, and 10.5% decline over 1 year, which can change how investors think about both upside potential and risk. Recent coverage has focused on Danaher in the...